Two-stage clinical trial stopping rules

Area of Science:

• Biostatistics
• Clinical Trial Design
• Statistical Inference

Background:

• Clinical trials often employ sequential or group sequential designs to allow for early stopping.
• Optimizing these designs involves balancing statistical rigor with efficiency in terms of sample size and trial duration.

Purpose of the Study:

• To derive nominal significance levels for the second stage of two-stage clinical trial stopping rules.
• To analyze the trade-off between statistical power and expected sample size (or early termination probability).
• To recommend a specific two-stage stopping rule intermediate to existing methods.

Main Methods:

• Derivation of second-stage nominal significance levels for overall significance levels of 0.01 and 0.05.
• Analysis considering first-stage sample sizes of one-half and two-thirds of the total.
• Graphical illustration of the power versus expected sample size trade-off.

Main Results:

• Calculated optimal significance levels for second-stage analysis across different scenarios.
• Demonstrated the inverse relationship between statistical power and expected sample size.
• Identified a specific, recommended two-stage stopping rule.

Conclusions:

• The derived significance levels provide a framework for efficient two-stage clinical trial designs.
• The recommended rule offers a practical balance between statistical power and sample size efficiency.
• These findings aid in designing more adaptive and resource-efficient clinical trials.